Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus. - Wikidata - wikimedia - TriplyDB

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.

http://www.wikidata.org/entity/Q36956933

about

Hepatitis B and human immunodeficiency virus co-infection Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.Combination versus sequential monotherapy in chronic HBV infection: a mathematical approach.HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone.Slow CD4+ T-Cell Recovery in Human Immunodeficiency Virus/Hepatitis B Virus-Coinfected Patients Initiating Truvada-Based Combination Antiretroviral Therapy in Botswana.Factors associated with delayed hepatitis B viral suppression on tenofovir among patients coinfected with HBV-HIV in the CNICS cohort Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras.Anti-hepatitis B activity of isoquinoline alkaloids of plant origin.HIV-hepatitis B virus co-infection: epidemiology, pathogenesis, and treatment.Five-year efficacy and safety of tenofovir-based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy.HBV-DNA levels predict overall mortality in HIV/HBV coinfected individuals.Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.Clinical Outcomes during Treatment Interruptions in Human Immunodeficiency Virus-Hepatitis B Virus Co-infected Patients from Sub-Saharan Africa.End-Stage Liver Disease in HIV Infection: An Avoidable Burden?Adherence to Nucleos(t)ide Analogue Therapies for Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis

P2860

Q26822862-9FF4D7B7-C40E-44A3-97BA-A7CB42082402 Q28547345-42C894D0-AF90-4064-AB98-A694335ECC66 Q34405008-031497D4-839B-4660-BDEE-7A253D9D49DD Q35422530-51ABAF39-AD09-4EEF-9C3D-D6C5ED3A22C4 Q35685474-ED5C314D-4C8C-44ED-80C9-4E12D3C21836 Q35892317-8F4F4827-BE2B-448A-A2C8-F073A7B2A8B5 Q35949791-9D5C4CD0-BFC4-4B9C-9260-9124BC264ADB Q36235577-2FC98EC5-DD6F-4F4D-A5EE-85205E8B738F Q37167046-F44F4C01-6B5E-4CBC-8ADF-DCCC8C4A6B0B Q37375386-E43493A1-1CF5-45A5-A769-2F3B29DDED8A Q37694907-A83C8DF8-F860-483C-95EE-3E9673DCBFE5 Q38406226-1D8B404D-6FCD-4693-AB9E-AC58C936839E Q39047732-83D1043A-785D-4238-B73D-466B3F6D8643 Q39425755-1CB0241F-5327-495A-86D0-47378DCF2CC1 Q40431628-02D98B9D-5DDF-4727-BC26-DD2E0D533497 Q40627202-4A769D35-D86F-427E-AFF0-1302B4B0CDFC Q41208197-3A7E0A49-F375-4DBF-9F55-A9015F970E7E Q41563379-57BED5B6-53CA-4101-95D0-1B813ACD570E Q42223115-563E7043-3A8C-4489-B5DA-75ED86722520 Q45324809-BAB5FE20-43AE-48AC-A9CC-22FA6A4C0E8D Q50777220-7FE973B3-F8DB-4E22-94E8-1DCC3B18E830 Q57069784-0917A3BC-48EC-4E4E-B7CF-28BC3066F588

P2860

Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.

http://www.wikidata.org/entity/Q36956933

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Patterns and causes of subopti ...... ith HIV and hepatitis B virus.

@en

type

label

Patterns and causes of subopti ...... ith HIV and hepatitis B virus.

@en

prefLabel

Patterns and causes of subopti ...... ith HIV and hepatitis B virus.

@en

P1433

Q36956933-60A9FAC2-0AFC-4C51-A887-9D6AE58C2EA0

P1476

Q36956933-C4D37AA0-69D5-49AF-ACB9-143EF700B576

P2093

Q36956933-03D30F53-CAF6-44D9-B836-0FC7E02EA16C

Q36956933-06263287-91F8-4B6C-81E9-8691C626C184

Q36956933-26BB388B-6457-4F5C-802C-504841ABB781

Q36956933-2E44A61C-C0FD-4043-B1F8-51A53DED7204

Q36956933-5122BCE5-E97F-45EE-B3EE-895BA3A2187E

Q36956933-7004D392-0613-4148-89DE-76E4904FA3C1

Q36956933-961D37A5-FDEF-4D55-9634-C97F4E8C0585

Q36956933-98B2EB07-FF4D-4F1D-A41D-6D83D6AF582A

Q36956933-C1AE1283-4F76-4552-9D27-97A88986A826

Q36956933-F005D379-5838-4DD5-A0EA-8D62202905C0

P2860

Q36956933-09012BDD-0C10-4C9B-82C4-9A8457B8872F

Q36956933-46BD752C-B9C3-4D0C-9711-D53B208D0998

Q36956933-5EEC12D5-1DDD-48DF-89B8-0A7DEC2FC495

Q36956933-75EA63C7-FD77-491E-AB12-0FDF99929972

Q36956933-855FF04E-E0FD-4565-ADB5-241B5642EBF4

Q36956933-8F84AD22-9279-4167-980B-C32E930DDEFE

Q36956933-931806B2-4A36-41D1-B4FD-B9CA5545206B

Q36956933-94DBF9EA-27AE-4FBC-91A0-3733A77239BE

Q36956933-CB4A3208-4C4B-4F84-AA5F-4C87D79D86E2

Q36956933-E64D4064-D7CC-49D1-A141-DAC5F2B4E9E8

P304

Q36956933-F31C9763-3FC6-4520-B8A9-860F3FC12AB3

P31

Q36956933-BE717D66-36C0-4971-BE03-31F380253169

P356

Q36956933-93831C0B-38A2-4E7A-911C-CCE15A1744C8

P407

Q36956933-942AFC82-B075-44B6-9E4B-D62C4562B19B

P433

Q36956933-5C5F7616-72B9-4E1A-941E-6273592CE684

P478

Q36956933-42015E33-3352-48D7-80AC-57A6A7353DB3

P50

Q36956933-108FC9B3-93FE-46FF-9E08-7EC89783DD7A

Q36956933-7E53BD74-9295-4CF6-BB11-F3DFC11C643E

Q36956933-D923667E-57F9-4022-B176-292870E23F83

Q36956933-FBE74106-28C1-455E-913E-A4ABF992A070

Q36956933-FDE5A6EA-96E8-449A-B357-09126D548470

P577

Q36956933-1A1CEF6C-2D10-4760-9628-526BF20287DE

P5875

Q36956933-E02FF164-E026-4F7C-BA3E-F6176AD45B4B

P698

Q36956933-E1EAB057-035E-45BE-A026-AB8A6CDBC076

P932

Q36956933-CB76E0E2-3695-401C-BC27-D962B31625C4

P356

P1433

Clinical Infectious Diseases

P1476

Patterns and causes of subopti ...... ith HIV and hepatitis B virus.

@en

P2093

Anchalee Avihingsanon

http://www.w3.org/2001/XMLSchema#string

Chloe L Thio

http://www.w3.org/2001/XMLSchema#string

Eric C Seaberg

http://www.w3.org/2001/XMLSchema#string

Gail V Matthews

http://www.w3.org/2001/XMLSchema#string

Gregory J Dore

http://www.w3.org/2001/XMLSchema#string

Joe Sasadeusz

http://www.w3.org/2001/XMLSchema#string

Melissa Saulynas

http://www.w3.org/2001/XMLSchema#string

Robert Finlayson

http://www.w3.org/2001/XMLSchema#string

Scott Bowden

http://www.w3.org/2001/XMLSchema#string

Stephen Locarnini

http://www.w3.org/2001/XMLSchema#string

P2860

Longitudinal data analysis for discrete and continuous outcomes

Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.

Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.

Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus.

An open-label study of tenofovir in HIV-1 and Hepatitis B virus co-infected individuals.

Long-term therapy with tenofovir is effective for patients co-infected with human immunodeficiency virus and hepatitis B virus.

Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.

Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir.

A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.

P304

e87-94

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIT002

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Sharon R. Lewin

Kiat Ruxrungtham

P577

2013-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

234124392

http://www.w3.org/2001/XMLSchema#string

P698

23315316

http://www.w3.org/2001/XMLSchema#string

P932

3693490

http://www.w3.org/2001/XMLSchema#string